Recombinant Human 4-1BB/TNFRSF9 His-tag Protein, CF

Recombinant Human 4-1BB/TNFRSF9 (Catalog # 9220-4B) has a molecular weight (MW) of 21.8 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).

When Recombinant Human 4-1BB/TNFRSF9 (Catalog # 9220-4B) is coated at 50 ng/mL, Recombinant Human 4-1BB Ligand/TNFSF9 Recombinant Human 4-1BB Ligand/ TNFSF9 (Catalog # 2295-4L) binds with a ED50 of 2.5-15 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human 4-1BB/TNFRSF9 His-tag Protein, CF Summary

• Additional Information: Analyzed by SEC-MALS.
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human 4-1BB/TNFRSF9/CD137 is immobilized at 50 ng/mL, 100 μL/well, the concentration of Recombinant Human 4‑1BB Ligand/TNFSF9 (Catalog # 2295-4L) that produces 50% of the optimal binding response is approximately 2.5-12.5 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human 4-1BB/TNFRSF9/CD137 protein
  Leu24-His183, with a C-terminal 6-His tag
• Accession #: Q07011
• N-terminal Sequence: Leu24
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 18 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 25-38 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human 4-1BB/TNFRSF9 His-tag Protein, CF

• 4-1BB ligand receptor
• 41BB
• 4-1BB
• CD137 antigen
• CD137
• CD137MGC2172
• CDw137
• FLJ43501
• ILA
• ILAhomolog of mouse 4-1BB
• induced by lymphocyte activation (ILA)
• interleukin-activated receptor, homolog of mouse Ly63
• receptor protein 4-1BB
• T cell antigen ILA
• T-cell antigen 4-1BB homolog
• T-cell antigen ILA
• TNFRSF9
• tumor necrosis factor receptor superfamily member 9
• tumor necrosis factor receptor superfamily, member 9

Background

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4⁺, CD8⁺, memory CD8⁺, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8⁺ T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells (9, 10).
4-1BB activation enhances CD8⁺ T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17).

1. Wang, C. et al. (2009) Immunol. Rev. 229:192.
2. Schwarz, H. et al. (1993) Gene 134:295.
3. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
4. Wen, T. et al. (2002) J. Immunol. 168:4897.
5. Pulle, G. et al. (2006) J. Immunol. 176:2739.
6. Zheng, G. et al. (2004) J. Immunol. 173:2428.
7. Kim, D. et al. (2008) J. Immunol. 180:2062.
8. Lee, S. et al. (2008) Nat. Immunol. 9:917.
9. Choi, B.K. et al. (2009) J. Immunol. 182:4107.
10. Nishimoto, H. et al. (2005) Blood 106:4241.
11. Saito, K. et al. (2004) J. Biol. Chem. 279:13555.
12. Lee, S. et al. (2005) J. Immunol. 174:6803.
13. Ma, B.Y. et al. (2005) Blood 106:2002.
14. Choi, B.K. et al. (2010) J. Immunol. 185:1404.
15. Kim, C. et al. (2011) Diabetes 60:3159.
16. Michel, J. et al. (1998) Eur. J. Immunol. 28:290.
17. Salih, H.R. et al. (2001) J. Immunol. 167:4059.

Publications for 4-1BB/TNFRSF9/CD137 (9220-4B)(1)

Publication using 9220-4B

• C Geuijen, P Tacken, LC Wang, R Klooster, PF van Loo, J Zhou, A Mondal, YB Liu, A Kramer, T Condamine, A Volgina, LJA Hendriks, H van der Ma, E Rovers, S Engels, F Fransen, R den Blanke, V Zondag-van, A Basmeleh, W Bartelink, A Kulkarni, W Marissen, CY Huang, L Hall, S Harvey, S Kim, M Martinez, S O'Brien, E Moon, S Albelda, C Kanellopou, S Stewart, H Nastri, ABH Bakker, P Scherle, T Logtenberg, G Hollis, J de Kruif, R Huber, PA Mayes, M Throsby A human CD137�PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade Nature Communications, 2021-07-21;12(1):4445. 2021-07-21 [PMID: 34290245] (Surface Plasmon Resonance, Human)

Bioinformatics

• Uniprot:
  • Q07011()